Hernando Garcia, MD
Pulmonary Disease · Miami Beach, FLNPI 1922000314
Payments from drug & device makers
Across 293 payments — averaging $271.46 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- United Therapeutics Corporation$69K
- Actelion Pharmaceuticals US, Inc.$4K
- Bayer$2K
- GSK$1K
- AstraZeneca$1K
- Inari Medical, Inc.$350
- plus $2K from 30 others
What the payments were for
- Consulting fees$10,20856%
- Travel & lodging$8004%
- Food & beverage$6,94138%
- Education$2822%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| United Therapeutics Corporation | 50 | $69,249 |
| Actelion Pharmaceuticals US, Inc. | 31 | $3,740 |
| Bayer | 11 | $1,546 |
| GSK | 89 | $1,239 |
| AstraZeneca | 37 | $1,126 |
| Inari Medical, Inc. | 2 | $350 |
| Boehringer Ingelheim | 9 | $299 |
| Amgen | 9 | $226 |
| Ambu Inc. | 2 | $188 |
| Stryker | 1 | $184 |
| Grifols USA, LLC | 3 | $176 |
| Sanofi | 6 | $155 |
| Takeda Pharmaceuticals U.S.A., Inc. | 7 | $148 |
| Inspire Medical Systems, Inc. | 1 | $140 |
| Merck | 4 | $100 |
| Mylan Specialty L.p. | 3 | $82 |
| Verona Pharma, Inc. | 4 | $79 |
| ANI Pharmaceuticals, Inc. | 2 | $60 |
| Philips North America LLC | 3 | $56 |
| Vyaire Medical, Inc. | 1 | $42 |
| Regeneron Healthcare Solutions, Inc. | 1 | $35 |
| Inogen, Inc. | 2 | $30 |
| Alnylam Pharmaceuticals Inc. | 1 | $28 |
| AbbVie | 1 | $26 |
| Johnson & Johnson | 2 | $26 |
| Myriad Genetic Laboratories, Inc. | 1 | $24 |
| Vapotherm Inc | 1 | $24 |
| Pulmonx Corporation | 1 | $22 |
| Neurocrine Biosciences, Inc. | 1 | $20 |
| Abbott | 1 | $20 |
| Halozyme Inc | 1 | $18 |
| Kowa Pharmaceuticals America, Inc. | 1 | $17 |
| Boston Scientific | 1 | $17 |
| Novo Nordisk | 1 | $16 |
| Cardinal Health 200 LLC | 1 | $15 |
| Angiodynamics, Inc. | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- OPSUMIT$2,807
- UPTRAVI$2,807
- Adempas$1,368
- FLOWTRIEVER CATHETER, S$534
- CT THROMBECTOMY SYSTEM KIT$534
- Inspire$140
- TAGRISSO$125
- BREZTRI$125
- Prolastin-C Liquid$125
- FASENRA$118
- TYVASO$117
How this compares
$79,537 in reported general payments places this provider in the 85th percentile of 953 pulmonary disease providers in Florida.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| UptraviSelexipag | 73 | $1,706,164 |
| OfevNintedanib Esylate | 90 | $1,116,692 |
| LetairisAmbrisentan | 26 | $332,198 |
| AdempasRiociguat | 22 | $310,155 |
| OpsumitMacitentan | 22 | $272,925 |
| Trelegy ElliptaFluticasone/Umeclidin/Vilanter | 295 | $198,261 |
| AdcircaTadalafil | 28 | $144,671 |
| Ambrisentan | 60 | $81,255 |
| Anoro ElliptaUmeclidinium Brm/Vilanterol Tr | 138 | $70,736 |
| Breo ElliptaFluticasone/Vilanterol | 162 | $66,692 |
| Breztri AerosphereBudesonide/Glycopyr/Formoterol | 84 | $54,639 |
| NucalaMepolizumab | 13 | $47,908 |
| Tadalafil | 16 | $20,214 |
| Pirfenidone | 24 | $18,947 |
| SymbicortBudesonide/Formoterol Fumarate | 60 | $17,887 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Actelion Pharmaceuticals US, Inc.Uptravi, Opsumit | $3,740 | $1,979,08995 claims |
| Boehringer IngelheimOfev | $299 | $1,116,69290 claims |
| GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta, Nucala, Incruse Ellipta | $1,239 | $394,035628 claims |
| BayerAdempas | $1,546 | $310,15522 claims |
| United Therapeutics CorporationAdcirca | $69,249 | $144,67128 claims |
| AstraZenecaBreztri Aerosphere, Symbicort | $1,126 | $72,526144 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 85th percentile of 953 pulmonary disease providers in Florida.
Other pulmonary disease in Miami Beach
- James KrainsonMiami$11.7M
- Jose DiazLeesburg$11.2M
- Carlos MartinezHomestead$9.2M
- Leonard DunnDunedin$7.6M
- Francis AverillClearwater$6.3M
- Charles BurgerJacksonville$5.6M
- Daniel LorchBrandon$5.5M
- Lourdes BoschMiami$4.2M
- Raj KarunakaraOcala$4M
- Neal WarshoffLoxahatchee$3.6M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.